Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 320873
1. Zare L, Sheikh Fathollahi M, Kazemi Arababadi M, Shamsizadeh A, Daneshpajouh B, Zainodini N, Allahtavakoli M: The Association Between C424c/A Polymorphism Within the IL-25 Gene and Multiple Sclerosis. Iran Red Crescent Med J; 2016 Sep;18(9):e25995

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Association Between C424c/A Polymorphism Within the IL-25 Gene and Multiple Sclerosis.
  • BACKGROUND: Multiple Sclerosis (MS) is a common autoimmune system disease which affects the central nervous system.
  • It has been documented that interleukin-25 (IL-25) plays key roles in suppressing Th1 responses, which is increased during MS.
  • OBJECTIVES: The aim of this study was to investigate the c424C/A polymorphism within the IL-25 gene in MS patients in comparison to healthy controls.
  • PATIENTS AND METHODS: In this case-control study, 74 patients with MS and 75 healthy controls were selected.
  • Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) was used in order to determine c424C/A polymorphism within the IL-25 gene.
  • RESULTS: The results showed that there was no statistical significant difference in distribution of genotype (AA, AC and CC) and allele (A and C) frequencies between MS patients and healthy controls (P = 0.901 and P = 0.728, respectively).
  • CONCLUSIONS: In conclusion, it appears that the c424C/A polymorphism within the IL-25 gene has no significant relationship with MS, and this polymorphism is probably not associated with MS complications, its onset and gender distribution.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Exp Immunol. 2014 Aug 15;3(2):91-6 [25143869.001]
  • [Cites] Nature. 2011 Aug 10;476(7359):214-9 [21833088.001]
  • [Cites] Ann Neurol. 2001 Jul;50(1):121-7 [11456302.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 2013 Nov;263 Suppl 2:S123-36 [24077889.001]
  • [Cites] Immunology. 2008 Oct;125(2):161-9 [18397264.001]
  • [Cites] Immunity. 2001 Dec;15(6):985-95 [11754819.001]
  • [Cites] Iran Red Crescent Med J. 2014 Jun;16(6):e17173 [25068045.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2009 Apr;80(4):386-91 [18931003.001]
  • [Cites] Brain. 2014 Mar;137(Pt 3):770-8 [24441172.001]
  • [Cites] Inflammation. 2012 Jun;35(3):797-802 [21909800.001]
  • [Cites] Mult Scler. 2002 Apr;8(2):115-8 [11990867.001]
  • [Cites] Neurology. 1991 May;41(5):685-91 [2027484.001]
  • [Cites] Iran J Radiol. 2013 Sep;10(3):128-32 [24348597.001]
  • [Cites] Ann Neurol. 2007 Apr;61(4):288-99 [17444504.001]
  • [Cites] Eur J Immunogenet. 2003 Oct;30(5):329-33 [14641539.001]
  • [Cites] Lancet. 2003 Feb 15;361(9357):545-52 [12598138.001]
  • (PMID = 28144453.001).
  • [ISSN] 2074-1804
  • [Journal-full-title] Iranian Red Crescent medical journal
  • [ISO-abbreviation] Iran Red Crescent Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Keywords] NOTNLM ; CCL25 / Genetic / Multiple Sclerosis / Polymorphism
  •  go-up   go-down


2. Sadovnick AD, Gu BJ, Traboulsee AL, Bernales CQ, Encarnacion M, Yee IM, Criscuoli MG, Huang X, Ou A, Milligan CJ, Petrou S, Wiley JS, Vilariño-Güell C: Purinergic receptors P2RX4 and P2RX7 in familial multiple sclerosis. Hum Mutat; 2017 Jun;38(6):736-744
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Purinergic receptors P2RX4 and P2RX7 in familial multiple sclerosis.
  • Genetic variants in the purinergic receptors P2RX4 and P2RX7 have been shown to affect susceptibility to multiple sclerosis (MS).
  • Sequencing analysis of P2RX4 and P2RX7 in 193 MS patients and 100 controls led to the identification of a rare three variant haplotype (P2RX7 rs140915863:C>T [p.T205M], P2RX7 rs201921967:A>G [p.N361S], and P2RX4 rs765866317:G>A [p.G135S]) segregating with disease in a multi-incident family with six family members diagnosed with MS (logarithm of odds = 3.07).
  • Our study nominates rare genetic variants in P2RX4 and P2RX7 as major genetic contributors to disease, further supporting a role for these purinergic receptors in MS and the disruption of transmembrane cation channels leading to impairment of phagocytosis as the pathological mechanisms of disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • [Cites] Cytometry A. 2014 Apr;85(4):313-21 [24132941.001]
  • [Cites] Nat Rev Immunol. 2012 Jun 15;12(7):532-47 [22699833.001]
  • [Cites] Pharmacol Ther. 2006 Nov;112(2):358-404 [16784779.001]
  • [Cites] Am J Hum Genet. 2011 Sep 9;89(3):398-406 [21907011.001]
  • [Cites] Nature. 2006 Aug 3;442(7102):527-32 [16885977.001]
  • [Cites] Biochem Biophys Res Commun. 2015 Nov 20;467(3):484-90 [26456657.001]
  • [Cites] Nat Rev Immunol. 2011 Mar;11(3):201-12 [21331080.001]
  • [Cites] Ann Neurol. 2001 Jul;50(1):121-7 [11456302.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jun;86(11):4175-8 [2726769.001]
  • [Cites] Am J Physiol Cell Physiol. 2009 Aug;297(2):C430-9 [19494237.001]
  • [Cites] Neurogenetics. 2014 Aug;15(3):165-9 [24770783.001]
  • [Cites] Hum Mol Genet. 2015 Oct 1;24(19):5644-54 [26188005.001]
  • [Cites] Parkinsonism Relat Disord. 2013 May;19(5):563-5 [23415606.001]
  • [Cites] J Immunol. 2007 Aug 1;179(3):1913-25 [17641058.001]
  • [Cites] Ann Neurol. 2005 Dec;58(6):840-6 [16283615.001]
  • [Cites] J Neuroimmunol. 2016 Feb 15;291:70-2 [26857497.001]
  • [Cites] Genes Immun. 2004 Nov;5(7):588-91 [15306849.001]
  • [Cites] Nature. 2016 Aug 17;536(7616):285-91 [27535533.001]
  • [Cites] J Cereb Blood Flow Metab. 2014 Mar;34(3):369-75 [24398940.001]
  • [Cites] Purinergic Signal. 2016 Mar;12 (1):59-67 [26739702.001]
  • [Cites] Blood. 2010 Feb 25;115(8):1621-31 [20007545.001]
  • [Cites] Nature. 2006 Mar 9;440(7081):228-32 [16407890.001]
  • [Cites] Hypertension. 2011 Dec;58(6):1086-92 [22068874.001]
  • [Cites] Mol Pharmacol. 2007 Dec;72(6):1447-56 [17785580.001]
  • [Cites] Can J Neurol Sci. 1998 Aug;25(3):216-21 [9706723.001]
  • [Cites] Blood. 1998 Nov 15;92 (10 ):3521-8 [9808543.001]
  • [Cites] Nat Genet. 2014 Mar;46(3):310-5 [24487276.001]
  • [Cites] BMC Neurol. 2006 Mar 02;6:12 [16512913.001]
  • [Cites] Ann Neurol. 1983 Mar;13(3):227-31 [6847134.001]
  • [Cites] J Immunol. 2011 Sep 1;187(5):2365-75 [21821797.001]
  • [Cites] Tissue Antigens. 2011 Nov;78(5):321-32 [21988719.001]
  • [Cites] Neuron. 2016 Jun 1;90(5):948-54 [27253448.001]
  • [Cites] Stem Cells. 2015 Feb;33(2):526-41 [25336287.001]
  • [Cites] Nucleic Acids Res. 2010 Sep;38(16):e164 [20601685.001]
  • (PMID = 28326637.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / / 126949-1; Canada / Canadian Institutes of Health Research / / 137051-1
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; P2RX4, P2RX7, P2X4, P2X7, variant / familial, Mendelian, multiple sclerosis / mutation
  •  go-up   go-down


3. Haibing X, Xu C, Jifu C, Wenshuang Z, Ling L, Yuzhen C, Yanjun H: Correlation between CTLA-4 gene rs221775A>G single nucleotide polymorphism and multiple sclerosis susceptibility. A meta-analysis. Open Med (Wars); 2016;11(1):264-269

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between CTLA-4 gene rs221775A>G single nucleotide polymorphism and multiple sclerosis susceptibility. A meta-analysis.
  • OBJECTIVE: The aim of this meta-analysis was to undertake a meta-analysis to evaluate the correlation between cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) gene rs221775 A>G single nucleotide polymorphism and the susceptibility of multiple sclerosis (MS) susceptibility.
  • METHOD: Published manuscripts about CTLA-4 gene rs221775A>G single nucleotide polymorphism and multiple sclerosis susceptibility were searched in the computerized bibliographic searches of Pubmed Embase and China National Knowledge Infrastructure (CNKI).
  • Potential studies were screened and data for 5025 MS patients and 4706 controls from 20 publications were included.
  • The association between CTLA-4 gene rs221775A>G single nucleotide polymorphism and multiple sclerosis susceptibility were demonstrated by odds ratio (OR) and 95% confidence interval (95%CI).
  • RESULTS: The pooled results showed no significant association between CTLA-4 gene rs221775A>G single nucleotide polymorphism and multiple sclerosis susceptibility for dominant genetic model [OR=1.02, 95%CI:0.90~1.05, (P=0.80)], homozygous genetic model [OR=0.85,95%CI:0.71 ~1.03,(P=0.10)] and recessive genetic model [OR=0.99,95% CI:0.89~1.10,(P=0.90)].
  • CONCLUSION: With current evidence, CTLA-4 gene rs221775A>G single nucleotide polymorphism had no association with the susceptibility of multiple sclerosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuroimmunol. 2005 Sep;166(1-2):197-201 [16005527.001]
  • [Cites] J Neuroimmunol. 2002 Oct;131(1-2):213-5 [12458055.001]
  • [Cites] Iran J Allergy Asthma Immunol. 2010 Dec;9(4):219-23 [21131701.001]
  • [Cites] Exp Mol Pathol. 2005 Feb;78(1):55-7 [15596061.001]
  • [Cites] Int J Immunogenet. 2011 Oct;38(5):419-26 [21797987.001]
  • [Cites] Lancet Neurol. 2009 Jan;8(1):6-8 [19081501.001]
  • [Cites] Acta Neurol Scand Suppl. 2011;(191):44-9 [21711256.001]
  • [Cites] J Neuroimmunol. 2005 Feb;159(1-2):225-9 [15652423.001]
  • [Cites] J Neuroimmunol. 2003 Jul;140(1-2):188-93 [12864988.001]
  • [Cites] J Neuroimmunol. 2003 Jan;134(1-2):133-41 [12507781.001]
  • [Cites] J Neuroimmunol. 2007 Jul;187(1-2):187-91 [17524498.001]
  • [Cites] Acta Neurol Scand. 2009 Dec;120(6):424-9 [19737153.001]
  • [Cites] J Neuroimmunol. 2004 Mar;148(1-2):218-30 [14975605.001]
  • [Cites] Mult Scler. 2008 Mar;14(2):153-8 [17942509.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):557-60 [12958120.001]
  • [Cites] J Neuroimmunol. 2002 Oct;131(1-2):208-12 [12458054.001]
  • [Cites] Immunity. 1997 Dec;7(6):885-95 [9430233.001]
  • [Cites] J Neurol Sci. 2001 Mar 1;184(2):143-7 [11239948.001]
  • [Cites] J Neuroimmunol. 2008 May 30;196(1-2):139-42 [18378005.001]
  • [Cites] J Neuroimmunol. 2006 Aug;177(1-2):146-50 [16769128.001]
  • [Cites] Mult Scler. 2011 Oct;17(10):1171-3 [21980150.001]
  • [Cites] Ann Neurol. 2003 Jul;54(1):119-22 [12838528.001]
  • [Cites] Acta Neurol Scand. 2004 Jul;110(1):67-71 [15180809.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2003;51(3):201-5 [12894875.001]
  • [Cites] Mol Biol (Mosk). 2002 Jul-Aug;36(4):643-8 [12173468.001]
  • [Cites] J Neuroimmunol. 1999 Jun 1;97(1-2):182-90 [10408973.001]
  • (PMID = 28352806.001).
  • [ISSN] 2391-5463
  • [Journal-full-title] Open medicine (Warsaw, Poland)
  • [ISO-abbreviation] Open Med (Wars)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; CTLA-4 gene / Meta-analysis / Multiple sclerosis / Polymorphism / Susceptibility
  •  go-up   go-down


Advertisement
4. Morandi E, Tanasescu R, Tarlinton RE, Constantinescu CS, Zhang W, Tench C, Gran B: The association between human endogenous retroviruses and multiple sclerosis: A systematic review and meta-analysis. PLoS One; 2017;12(2):e0172415

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association between human endogenous retroviruses and multiple sclerosis: A systematic review and meta-analysis.
  • BACKGROUND: The interaction between genetic and environmental factors is crucial to multiple sclerosis (MS) pathogenesis.
  • Human Endogenous Retroviruses (HERVs) are endogenous viral elements of the human genome whose expression is associated with MS.
  • OBJECTIVE: To perform a systematic review and meta-analysis and to assess qualitative and quantitative evidence on the expression of HERV families in MS patients.
  • METHODS: Medline, Embase and the Cochrane Library were searched for published studies on the association of HERVs and MS.
  • The analysis showed an association between expression of all HERV families and MS.
  • Results from meta-analyses of HERV-W were OR = 22.66 (95%CI 6.32 to 81.20) from 4 studies investigating MSRV/HERV-W (MS-associated retrovirus) envelope mRNA in peripheral blood mononuclear cells, OR = 44.11 (95%CI 12.95 to 150.30) from 6 studies of MSRV/HERV-W polymerase mRNA in serum/plasma and OR = 6.00 (95%CI 3.35 to 10.74) from 4 studies of MSRV/HERV-W polymerase mRNA in CSF.
  • CONCLUSIONS: This systematic review and meta-analysis shows an association between expression of HERVs, and in particular the HERV-W family, and MS.
  • [MeSH-major] Endogenous Retroviruses / pathogenicity. Multiple Sclerosis / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mult Scler. 1996 Oct;2(3):133-6 [9345377.001]
  • [Cites] Ann Neurol. 2001 Oct;50(4):434-42 [11601494.001]
  • [Cites] Int Immunol. 2015 Nov;27(11):545-53 [25957268.001]
  • [Cites] Virus Genes. 2003 May;26(3):291-315 [12876457.001]
  • [Cites] Lancet. 1998 Jan 3;351(9095):33 [9433428.001]
  • [Cites] Retrovirology. 2009 Apr 15;6:37 [19368703.001]
  • [Cites] Acta Neurol Scand. 2000 Apr;101(4):229-38 [10770518.001]
  • [Cites] PLoS One. 2011 Feb 02;6(2):e16652 [21311761.001]
  • [Cites] Nat Neurosci. 2004 Oct;7(10):1088-95 [15452578.001]
  • [Cites] Neurol Sci. 2001 Apr;22(2):171-3 [11603622.001]
  • [Cites] Mult Scler. 2012 Oct;18(10):1384-94 [22457343.001]
  • [Cites] J Virol Methods. 2009 Oct;161(1):98-106 [19505508.001]
  • [Cites] AIDS Res Hum Retroviruses. 2007 Oct;23(10):1251-6 [17961112.001]
  • [Cites] AIDS Res Hum Retroviruses. 2006 Dec;22(12):1253-9 [17209768.001]
  • [Cites] AIDS Res Hum Retroviruses. 2008 Mar;24(3):363-5 [18327982.001]
  • [Cites] Mult Scler. 2008 Jun;14(5):595-601 [18566025.001]
  • [Cites] Pol J Pharmacol. 2003 Sep-Oct;55(5):869-75 [14704480.001]
  • [Cites] Virol J. 2012 Sep 08;9:188 [22958517.001]
  • [Cites] Dis Markers. 1998 Feb;13(4):251-5 [9553740.001]
  • [Cites] Autoimmunity. 1999;29(2):141-5 [10433076.001]
  • [Cites] Retrovirology. 2014 Jan 09;11:2 [24405691.001]
  • [Cites] AIDS Res Hum Retroviruses. 2009 Mar;25(3):377-8; author reply 379-81 [19292592.001]
  • [Cites] Int J Biomed Sci. 2007 Dec;3(4):292-7 [23675056.001]
  • [Cites] Front Microbiol. 2013 Jun 26;4:172 [23805135.001]
  • [Cites] J Immunol. 2006 Jun 15;176(12):7636-44 [16751411.001]
  • [Cites] PLoS One. 2014 Mar 03;9(3):e90182 [24594754.001]
  • [Cites] PLoS One. 2011;6(10):e26438 [22039488.001]
  • [Cites] Neurology. 2002 Feb 12;58(3):471-3 [11839854.001]
  • [Cites] Genomics. 2005 Sep;86(3):337-41 [16024218.001]
  • [Cites] Mult Scler. 2003 Feb;9(1):6-15 [12617261.001]
  • [Cites] Immunol Res. 2016 Feb;64(1):55-63 [26091722.001]
  • [Cites] FEBS Lett. 1997 Aug 25;413(3):477-85 [9303559.001]
  • [Cites] PLoS One. 2013 Dec 06;8(12):e80128 [24324591.001]
  • [Cites] PLoS Med. 2009 Jul 21;6(7):e1000100 [19621070.001]
  • [Cites] Metab Brain Dis. 2006 Sep;21(2-3):163-9 [16865539.001]
  • [Cites] J Virol. 2012 Apr;86(7):3713-22 [22278236.001]
  • [Cites] J Neurovirol. 2005 Feb;11(1):23-33 [15804956.001]
  • [Cites] Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):E2326-34 [27001843.001]
  • [Cites] Acta Neurol Scand. 2001 Jan;103(1):20-6 [11153884.001]
  • [Cites] Mult Scler Relat Disord. 2016 Jul;8:11-8 [27456869.001]
  • [Cites] Ann Neurol. 2013 Nov;74(5):721-32 [23836485.001]
  • [Cites] J Neurovirol. 2003 Feb;9(1):112-7 [12587074.001]
  • [Cites] Mult Scler. 2008 Nov;14(9):1175-80 [18701576.001]
  • [Cites] PLoS One. 2012;7(9):e44991 [23028727.001]
  • [Cites] Retrovirology. 2009 Nov 16;6:104 [19917105.001]
  • [Cites] J Virol. 2013 Dec;87(24):13837-52 [24109235.001]
  • [Cites] Lancet Neurol. 2016 Jan;15(1):9-11 [26700897.001]
  • [Cites] Eur J Neurol. 2002 Jul;9(4):329-41 [12099914.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7583-8 [9207135.001]
  • [Cites] PLoS One. 2013;8(1):e53623 [23308264.001]
  • [Cites] Acta Neurol Scand Suppl. 1997;169:38-44 [9174639.001]
  • [Cites] J Gen Virol. 2007 Jan;88(Pt 1):264-74 [17170460.001]
  • [Cites] Mult Scler. 2012 Dec;18(12):1721-36 [22457345.001]
  • [Cites] PLoS One. 2013 Apr 25;8(4):e62090 [23634223.001]
  • [Cites] Retrovirology. 2016 Sep 09;13(1):67 [27613107.001]
  • [Cites] Rev Med Virol. 2005 May-Jun;15(3):179-211 [15782388.001]
  • [Cites] J Neurol Sci. 2009 Nov 15;286(1-2):65-72 [19447411.001]
  • [Cites] Dis Markers. 2000;16(3-4):101-4 [11381188.001]
  • [Cites] Ann Neurol. 2007 Apr;61(4):288-99 [17444504.001]
  • (PMID = 28207850.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  •  go-up   go-down


5. Haile Y, Deng X, Ortiz-Sandoval C, Tahbaz N, Janowicz A, Lu JQ, Kerr BJ, Gutowski NJ, Holley JE, Eggleton P, Giuliani F, Simmen T: Rab32 connects ER stress to mitochondrial defects in multiple sclerosis. J Neuroinflammation; 2017 Jan 23;14(1):19

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rab32 connects ER stress to mitochondrial defects in multiple sclerosis.
  • BACKGROUND: Endoplasmic reticulum (ER) stress is a hallmark of neurodegenerative diseases such as multiple sclerosis (MS).
  • However, this physiological mechanism has multiple manifestations that range from impaired clearance of unfolded proteins to altered mitochondrial dynamics and apoptosis.
  • METHODS: We assessed Rab32 expression in MS patient and experimental autoimmune encephalomyelitis (EAE) tissue, via observation of mitochondria in primary neurons and via monitoring of survival of neuronal cells upon increased Rab32 expression.
  • RESULTS: We found that the induction of Rab32 and other MAM proteins correlates with ER stress proteins in MS brain, as well as in EAE, and occurs in multiple central nervous system (CNS) cell types.
  • CONCLUSIONS: ER stress is strongly associated with Rab32 upregulation in the progression of MS, leading to mitochondrial dysfunction and neuronal death.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28115010.001).
  • [ISSN] 1742-2094
  • [Journal-full-title] Journal of neuroinflammation
  • [ISO-abbreviation] J Neuroinflammation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Endoplasmic reticulum / Mitochondria / Multiple sclerosis / Unfolded protein response (UPR)
  •  go-up   go-down


6. Singh AK, Novakova L, Axelsson M, Malmeström C, Zetterberg H, Lycke J, Cardell SL: High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis. Front Immunol; 2017;8:260

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis.
  • We have identified a population of T lymphocytes in peripheral blood, Vδ1 TCRγδ T lymphocytes, which unexpectedly was uniquely expressing high production of interferon-γ in newly diagnosed, untreated multiple sclerosis (MS) patients.
  • IFN-γ production in this population distinctly correlated to parameters of clinical disease activity, inflammation, and neuronal damage.
  • A biomarker and early sign of demyelinating disease in MS is much warranted and would help identify immunopathogenesis and prognosis of disease as well as monitor success with adequate treatment.
  • The present study identifies the Vδ1 T lymphocytes as an early marker of MS and a possible link to understanding the disease etiology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Immunol. 2006 May;43(12):2002-11 [16423401.001]
  • [Cites] J Neuroimmunol. 1992 Oct;40(2-3):211-8 [1430152.001]
  • [Cites] J Exp Med. 2003 Aug 4;198(3):391-7 [12900516.001]
  • [Cites] Neuroimmunomodulation. 2015;22(3):181-95 [24852748.001]
  • [Cites] J Immunol. 2016 Feb 15;196 (4):1933-42 [26755823.001]
  • [Cites] J Exp Med. 2004 Jul 5;200(1):79-87 [15238607.001]
  • [Cites] Immunity. 2013 Dec 12;39(6):1032-42 [24239091.001]
  • [Cites] Eur J Immunol. 1999 May;29(5):1667-75 [10359121.001]
  • [Cites] Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13073-8 [23878218.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):947-57 [15051763.001]
  • [Cites] Mol Ther. 2014 Aug;22(8):1416-22 [24895997.001]
  • [Cites] Immunity. 2009 Aug 21;31(2):331-41 [19682929.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8389-94 [12829791.001]
  • [Cites] Clin Exp Immunol. 2009 Sep;157(3):385-94 [19664147.001]
  • [Cites] Neurology. 2009 Dec 1;73(22):1914-22 [19949037.001]
  • [Cites] Nature. 2010 Oct 21;467(7318):967-71 [20962846.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6611-8 [19395673.001]
  • [Cites] Nat Immunol. 2012 Oct;13(10):991-9 [22961052.001]
  • [Cites] Scand J Immunol. 1989 Dec;30(6):665-72 [2481336.001]
  • [Cites] Acta Neurol Scand. 2017 Jan;135(1):17-24 [27558404.001]
  • [Cites] Ann Neurol. 2011 Feb;69(2):292-302 [21387374.001]
  • [Cites] Eur J Immunol. 1999 Dec;29(12):4060-71 [10602017.001]
  • [Cites] Eur J Immunol. 2012 Sep;42(9):2505-10 [22829134.001]
  • [Cites] Immunology. 2015 Sep;146(1):1-10 [26032048.001]
  • [Cites] Nat Immunol. 2011 Mar;12(3):255-63 [21278737.001]
  • [Cites] J Virol. 1996 Jun;70(6):3545-50 [8648688.001]
  • [Cites] J Immunol. 2008 Sep 15;181(6):3750-4 [18768826.001]
  • [Cites] Eur J Immunol. 2009 Jul;39(7):1794-806 [19544311.001]
  • [Cites] Trends Mol Med. 2015 Apr;21(4):233-44 [25771098.001]
  • [Cites] Lancet. 1987 Apr 18;1(8538):893-5 [2882294.001]
  • [Cites] Neurology. 2003 Dec 23;61(12):1720-5 [14694036.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4588-92 [1374907.001]
  • [Cites] Curr Mol Med. 2009 Feb;9(1):15-22 [19199938.001]
  • [Cites] Nat Immunol. 2011 Jun;12(6):568-75 [21516111.001]
  • [Cites] Nat Immunol. 2011 Jun;12(6):560-7 [21516112.001]
  • [Cites] Front Immunol. 2015 Sep 30;6:503 [26483793.001]
  • [Cites] N Engl J Med. 2006 Mar 2;354(9):899-910 [16510744.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):923-7 [8430106.001]
  • [Cites] J Neurosci Methods. 1994 Mar;51(2):197-204 [8051950.001]
  • [Cites] J Immunol. 2009 Dec 1;183(11):7169-77 [19890056.001]
  • [Cites] J Exp Med. 2010 Apr 12;207(4):807-21 [20368575.001]
  • [Cites] Acta Neuropathol. 2013 Oct;126(4):501-15 [23934116.001]
  • [Cites] Eur J Immunol. 2014 Oct;44(10):3119-28 [25043505.001]
  • [Cites] Nat Rev Immunol. 2013 Feb;13(2):88-100 [23348415.001]
  • [Cites] Clin Immunol. 2015 Nov;161(1):51-8 [26143623.001]
  • [Cites] JAMA Neurol. 2013 Mar 1;70(3):345-51 [23599932.001]
  • [Cites] Neurology. 2009 Jun 2;72(22):1922-30 [19487650.001]
  • [Cites] Immunol Today. 1989 Jun;10(6):186-8 [2526644.001]
  • [Cites] PLoS One. 2015 Sep 14;10(9):e0137429 [26367776.001]
  • [Cites] Annu Rev Immunol. 2014;32:257-81 [24438352.001]
  • [Cites] Eur J Immunol. 2010 Aug;40(8):2174-81 [20486123.001]
  • [Cites] Immunity. 2014 May 15;40(5):785-800 [24816404.001]
  • [Cites] Nat Immunol. 2007 Sep;8(9):913-9 [17712344.001]
  • [Cites] Annu Rev Immunol. 2000;18:975-1026 [10837080.001]
  • [Cites] Sci Rep. 2016 Jun 27;6:28484 [27346372.001]
  • (PMID = 28337205.001).
  • [ISSN] 1664-3224
  • [Journal-full-title] Frontiers in immunology
  • [ISO-abbreviation] Front Immunol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Vdelta1 T cells / cerebrospinal fluid / gamma-delta T cells / interferon-gamma / multiple sclerosis / natalizumab
  •  go-up   go-down


7. Maver A, Lavtar P, Ristić S, Stopinšek S, Simčič S, Hočevar K, Sepčić J, Drulović J, Pekmezović T, Novaković I, Alenka H, Rudolf G, Šega S, Starčević-Čizmarević N, Palandačić A, Zamolo G, Kapović M, Likar T, Peterlin B: Identification of rare genetic variation of NLRP1 gene in familial multiple sclerosis. Sci Rep; 2017 Jun 16;7(1):3715

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of rare genetic variation of NLRP1 gene in familial multiple sclerosis.
  • The genetic etiology and the contribution of rare genetic variation in multiple sclerosis (MS) has not yet been elucidated.
  • Although familial forms of MS have been described, no convincing rare and penetrant variants have been reported to date.
  • We aimed to characterize the contribution of rare genetic variation in familial and sporadic MS and have identified a family with two sibs affected by concomitant MS and malignant melanoma (MM).
  • We performed whole exome sequencing in this primary family and 38 multiplex MS families and 44 sporadic MS cases and performed transcriptional and immunologic assessment of the identified variants.
  • We identified a potentially causative homozygous missense variant in NLRP1 gene (Gly587Ser) in the primary family.
  • Stimulation of peripheral blood mononuclear cells from MS patients with putatively pathogenic NLRP1 variants showed an increase in IL-1B gene expression and active cytokine IL-1β production, as well as global activation of NLRP1-driven immunologic pathways.
  • We report a novel familial association of MS and MM, and propose a possible underlying genetic basis in NLRP1 gene.
  • Furthermore, we provide initial evidence of the broader implications of NLRP1-related pathway dysfunction in MS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Neurol. 2015 Mar;14(3):263-73 [25662901.001]
  • [Cites] EMBO Mol Med. 2013 Jun;5(6):814-26 [23666718.001]
  • [Cites] Neurology. 1990 Nov;40(11):1735-9 [2234430.001]
  • [Cites] Nucleic Acids Res. 2009 Jul;37(Web Server issue):W593-9 [19465395.001]
  • [Cites] Trends Mol Med. 2013 Oct;19(10):604-13 [24007818.001]
  • [Cites] J Neuroimmunol. 2014 May 15;270(1-2):56-60 [24657029.001]
  • [Cites] J Neurol Sci. 2014 Aug 15;343(1-2):1 [24857353.001]
  • [Cites] Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2952-6 [23382179.001]
  • [Cites] Brain. 2015 Mar;138(Pt 3):644-52 [25586466.001]
  • [Cites] Ann Neurol. 2011 Feb;69(2):292-302 [21387374.001]
  • [Cites] Mult Scler. 2011 Jan;17(1):43-56 [20855355.001]
  • [Cites] Mult Scler. 2004 Oct;10(5):575-81 [15471376.001]
  • [Cites] Neurology. 2012 Jul 31;79(5):406-11 [22744673.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3935-40 [19223583.001]
  • [Cites] Mol Immunol. 2015 Feb;63(2):521-9 [25458313.001]
  • [Cites] J Biol Chem. 2010 Feb 26;285(9):6477-88 [20038581.001]
  • [Cites] Lancet Neurol. 2004 Dec;3(12):709-18 [15556803.001]
  • [Cites] CSH Protoc. 2007 Sep 01;2007:pdb.prot4841 [21357174.001]
  • [Cites] Ann Neurol. 2011 Dec;70(6):881-6 [22190362.001]
  • [Cites] Am J Hum Genet. 2002 Jun;70(6):1498-506 [11992256.001]
  • [Cites] Nat Rev Drug Discov. 2012 Aug;11(8):633-52 [22850787.001]
  • [Cites] Immunity. 2012 Dec 14;37(6):1009-23 [23219391.001]
  • [Cites] Mol Cell Biol. 2013 Oct;33(19):3728-34 [23897428.001]
  • [Cites] Oncogene. 2017 Mar 06;:null [28263976.001]
  • [Cites] J Neuroimmunol. 2002 May;126(1-2):172-9 [12020968.001]
  • [Cites] Pigment Cell Melanoma Res. 2012 Jul;25(4):506-13 [22524199.001]
  • [Cites] Neuron. 2016 Jun 1;90(5):948-54 [27253448.001]
  • (PMID = 28623311.001).
  • [ISSN] 2045-2322
  • [Journal-full-title] Scientific reports
  • [ISO-abbreviation] Sci Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Sabatino JJ Jr, Newsome SD: Stiff person syndrome masquerading as multiple sclerosis. J Neurol Sci; 2017 Jan 15;372:297-299
MedlinePlus Health Information. consumer health - Multiple Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stiff person syndrome masquerading as multiple sclerosis.
  • BACKGROUND: Stiff person syndrome (SPS) is a rare neuroimmunological disorder presenting with a wide variety of signs and symptoms that mimic neuro-inflammatory diseases, such as multiple sclerosis (MS), thus delaying diagnosis.
  • METHODS: We performed a retrospective chart review of over 100 patients with SPS who were treated at Johns Hopkins Hospital and identified five patients previously diagnosed with MS.
  • Mean time to SPS diagnosis was 5.5years.
  • They presented with typical SPS features (axial/leg spasms, torso rigidity, hyperlordosis, and gait instability) as well as atypical features (hemiparesis, hemisensory dysfunction, fine motor impairment) and were all initially given a diagnosis of MS.
  • SPS diagnosis was supported by elevated anti-glutamic acid decarboxylase (GAD65) antibodies in each patient.
  • Two patients were treated with disease-modifying therapies for MS before being diagnosed with SPS.
  • Following diagnosis with SPS, the patients were treated with varying combinations of immunosuppressants and symptomatic therapies resulting in stabilization or improvement in four of the patients.
  • CONCLUSION: We present five patients with SPS, who were initially thought to have MS, including one patient treated with three different MS therapies due to "disease progression".
  • These cases demonstrate the need to consider less common neuroimmunological disorders, such as SPS, especially in patients with atypical features for MS.
  • [MeSH-major] Multiple Sclerosis / physiopathology. Stiff-Person Syndrome / diagnosis

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • Genetic Alliance. consumer health - Stiff person syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 Elsevier B.V. All rights reserved.
  • (PMID = 28017232.001).
  • [ISSN] 1878-5883
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Autoantibodies; EC 4.1.1.15 / Glutamate Decarboxylase; EC 4.1.1.15 / glutamate decarboxylase 2
  • [Keywords] NOTNLM ; Multiple sclerosis (major topic) / Neuroinflammatory diseases (major topic) / Stiff person syndrome (major topic)
  •  go-up   go-down


9. Shawkatová I, Javor J, Párnická Z, Bucová M, Čopíková-Cudráková D, Michalík J, Gmitterová K, Čierny D, Buc M, Ďurmanová V: Analysis of ICAM1 gene polymorphism in Slovak multiple sclerosis patients. Folia Microbiol (Praha); 2017 Jul;62(4):287-293
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of ICAM1 gene polymorphism in Slovak multiple sclerosis patients.
  • Infiltration of immune cells into CNS is one of the essential events in multiple sclerosis (MS) development.
  • Therefore, the ICAM1 gene containing two important single-nucleotide polymorphisms (SNPs) belongs to candidate loci with possible involvement in MS susceptibility and/or severity.
  • The objective of our case-control study was to analyze the association of two functional ICAM1 polymorphisms rs1799969 (or G241R) and rs5498 (or K469E) with susceptibility to MS and evaluate their influence on the age at disease onset, severity, neurological disability and progression rate.
  • Two hundred forty-eight MS subjects (mean 39.2 years) and 208 age-matched controls (mean 35.6 years) were involved in the study.
  • Presence of the rs3135388 polymorphism tagging the major MS risk allele HLA-DRB1*15:01 allele was determined as well.
  • Our analysis revealed no statistically significant association of ICAM1 polymorphisms with risk of MS development in the Slovak population.
  • Stratification of study cohorts by gender, age at onset and presence of the HLA-DRB1*15:01 risk allele showed only moderate changes.
  • Correlation of clinical findings as age at onset, Kurtzke Expanded Disability Status Scale, Multiple Sclerosis Severity Score and progression index with ICAM1 genotypes in MS patients revealed no significant association; however, patients with earlier onset of MS showed slightly higher frequencies of the homozygous G allele at rs5498 in comparison to other genotypes (P = 0.04), suggesting that GG carriers tend to induce MS at an earlier age.
  • [MeSH-major] Intercellular Adhesion Molecule-1 / genetics. Multiple Sclerosis / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Adult. Alleles. Case-Control Studies. Female. Genetic Predisposition to Disease. Genotype. HLA-DRB1 Chains / genetics. Humans. Male. Middle Aged. Slovakia. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28130760.001).
  • [ISSN] 1874-9356
  • [Journal-full-title] Folia microbiologica
  • [ISO-abbreviation] Folia Microbiol. (Praha)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-DRB1 Chains; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


10. Zhou Y, Fang L, Peng L, Qiu W: TLR9 and its signaling pathway in multiple sclerosis. J Neurol Sci; 2017 Feb 15;373:95-99
MedlinePlus Health Information. consumer health - Multiple Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TLR9 and its signaling pathway in multiple sclerosis.
  • Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by axonal destruction and demyelination, which etiology and immunopathogenesis still remains uncertain.
  • Although several lines of evidence show that myelin-reactive T cells play an essential role in the pathogenesis of MS, recent findings have pointed to the relevance of innate immune system such as Toll-like receptors (TLRs).
  • In this article, we discuss the role of TLR9 and its signaling pathway in the development of MS and present some therapeutic strategies based on in vivo and in vitro findings.
  • [MeSH-major] Multiple Sclerosis / metabolism. Toll-Like Receptor 9 / metabolism
  • [MeSH-minor] Animals. Humans. Signal Transduction

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016 Elsevier B.V. All rights reserved.
  • (PMID = 28131238.001).
  • [ISSN] 1878-5883
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Toll-Like Receptor 9
  • [Keywords] NOTNLM ; Multiple sclerosis / NF-κB / TLR9
  •  go-up   go-down






Advertisement